UniProtKB/Swiss-Prot Q8WVQ1: Variant p.Arg300His

Soluble calcium-activated nucleotidase 1
Gene: CANT1
Chromosomal location: 17q25.3
Variant information

Variant position:  300
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants have been found in patients and disease-association is reported in literature. However, this classification is not a definitive assessment of variant pathogenicity.
  • Polymorphism: No disease-association has been reported.
  • Unclassified: Variants have been found in patients but disease-association remains unclear.

Residue change:  From Arginine (R) to Histidine (H) at position 300 (R300H, p.Arg300His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In DBQD1.
Any additional useful information about the variant.



Sequence information

Variant position:  300
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  401
The length of the canonical sequence.

Location on the sequence:   YLIHESACWSDTLQRWFFLP  R RASQERYSEKDDERKGANLL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YLIHESACWSDTLQRWFFLPRRASQERYSEKDDERKGANLL

Mouse                         YLIHESACWSDTLQRWFFLPRRASHERYSEKDDERKGSNLL

Rat                           YLIHESACWSDTLQRWFFLPRRASHERYSEREDERKGSNLL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 401 Soluble calcium-activated nucleotidase 1
Topological domain 63 – 401 Lumenal
Metal binding 284 – 284 Calcium
Alternative sequence 246 – 401 Missing. In isoform 2.
Mutagenesis 301 – 301 R -> A. Reduces activity by 99%.
Beta strand 300 – 305


Literature citations

Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis.
Nizon M.; Huber C.; De Leonardis F.; Merrina R.; Forlino A.; Fradin M.; Tuysuz B.; Abu-Libdeh B.Y.; Alanay Y.; Albrecht B.; Al-Gazali L.; Basaran S.Y.; Clayton-Smith J.; Desir J.; Gill H.; Greally M.T.; Koparir E.; van Maarle M.C.; Mackay S.; Mortier G.; Morton J.; Sillence D.; Vilain C.; Young I.; Zerres K.; Le Merrer M.; Munnich A.; Le Goff C.; Rossi A.; Cormier-Daire V.;
Hum. Mutat. 33:1261-1266(2012)
Cited for: FUNCTION IN PROTEOGLYCAN SYNTHESIS; VARIANTS DBQD1 HIS-300; ARG-303 AND ASN-374;

Identification of CANT1 mutations in Desbuquois dysplasia.
Huber C.; Oules B.; Bertoli M.; Chami M.; Fradin M.; Alanay Y.; Al-Gazali L.I.; Ausems M.G.; Bitoun P.; Cavalcanti D.P.; Krebs A.; Le Merrer M.; Mortier G.; Shafeghati Y.; Superti-Furga A.; Robertson S.P.; Le Goff C.; Muda A.O.; Paterlini-Brechot P.; Munnich A.; Cormier-Daire V.;
Am. J. Hum. Genet. 85:706-710(2009)
Cited for: VARIANTS DBQD1 LEU-299; CYS-300 AND HIS-300;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.